Chronic Hepatitis C virus infection is common and often produces a progressive disease.
Some studies suggest that Hepatitis C related complications will increase in the future.
Dr Butia and colleagues from Spain estimated the future morbidity, mortality and costs of chronic Hepatitis C virus infection in a cohort of patients infected by Hepatitis C and evaluated the impact of Hepatitis C virus therapy.
The investigators used a mathematical model to project the Hepatitis C related complications and costs over the next 30 years.
|Treating 50% of the population with Hepatitis C will result in a reduction of 26% in morbidity and 20% in mortality|
|Journal of Hepatology|
The researchers examined a cohort of 419,895 infected patients representing the Hepatitis C infected population in Spain.
The team also projected the impact of Hepatitis C virus therapy with peginterferon and ribavirin in this population.
The research team noted that a gradual decline in the infected population is to be expected in the future.
In addition, the researchers reported that the proportion of patients with cirrhosis will increase by up to 14%.
Morbidity associated with Hepatitis C infection will increase by up to 10% by the year 2030 with a subsequent increment in Hepatitis C related costs.
The investigators also found that treating from 10% to 50% of the population with Hepatitis C will result in a reduction of 6% and 26% in morbidity and 4% and 20% in mortality, respectively.
The team observed that the cost per year of life gained ranges from 6078 € for a 29 year old patient to 8911 € for a 59 year old patient.
Dr Butia’s team concluded, “ In the future, Hepatitis C infection mortality, morbidity and associated costs will increase.”
“Treatment of the chronic Hepatitis C infected population can eradicate the infection, increase patients' survival and reduce the need for liver transplantation, making this a cost-effective strategy.”